| ￥3500 | |
| Z04889-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized OSMR, His, Cynomolgus at 2μg/ml (100μl/well) on the plate can bind AntiOSMR Antibody, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 82.04 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 110-130 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | OSMR is targeted to the mitochondrial matrix via the presequence translocase-associated motor complex components, mtHSP70 and TIM44. OSMR interacts with NADH ubiquinone oxidoreductase 1/2 (NDUFS1/2) of complex I and promotes mitochondrial respiration. Deletion of OSMR impairs spare respiratory capacity, increases reactive oxygen species, and sensitizes BTSCs to IR-induced cell death. |
| Synonyms | IL-31R subunit beta; IL-31R-beta; IL-31RB; OSMR beta; OSMR; OSMRB; OSMRBMGC150626; PLCA1 ;IL-31R subunit β; IL-31R-β; OSMR β |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
